← The Wire
ACADNasdaq
ACADIA PHARMACEUTICALS INC
Pharmaceutical Preparations · DE · CIK 1070494
Develops and commercializes treatments for neurological and rare diseases, including Parkinson's disease psychosis and Rett syndrome
red 8-K · 90d⚡ Elevated coverage
$3.61B
Market cap
$25.20
Last close
-0.5%
1D
+14.1%
5D
2.1M
Volume
Price · last 39 sessions+13.6%
May 4L $20.48 · H $25.32Jun 29
289
Total filings
May 29, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteMay 29, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 6, 20268-KExecutive Change · Reg FD DisclosureMay 1, 2026DEF 14ADEF 14AApr 24, 20268-KExecutive ChangeMar 5, 202610-K10-KFeb 26, 2026SC 13D/ASC 13D/AFeb 26, 20268-KResults of OperationsFeb 25, 20268-KResults of Operations · Reg FD DisclosureJan 13, 202610-Q10-QNov 6, 20258-KResults of OperationsNov 5, 20258-KExecutive ChangeNov 3, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 6, 20258-KCompany UpdateJun 10, 20258-KShareholder VoteMay 29, 20258-KMaterial Agreement · Company UpdateMay 20, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 7, 2025DEF 14ADEF 14AApr 25, 20258-KBylaw AmendmentApr 16, 202510-K10-KFeb 27, 20258-KResults of OperationsFeb 26, 20258-KAcquisition / DispositionDec 11, 20248-KExecutive ChangeNov 20, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 6, 20248-KExecutive ChangeSep 23, 202410-Q10-QAug 7, 20248-KResults of OperationsAug 6, 20248-KExecutive Change · Shareholder VoteMay 29, 202410-Q10-QMay 9, 20248-KResults of OperationsMay 8, 2024DEF 14ADEF 14AApr 26, 20248-KCompany UpdateMar 11, 202410-K10-KFeb 28, 20248-KResults of OperationsFeb 27, 2024SC 13GSC 13GFeb 14, 20248-KExecutive ChangeJan 31, 20248-KCompany UpdateNov 21, 202310-Q10-QNov 3, 20238-KResults of OperationsNov 2, 202310-Q10-QAug 3, 20238-KResults of OperationsAug 2, 20238-KMaterial Agreement · Results of OperationsJul 18, 20238-KShareholder VoteJun 2, 202310-Q10-QMay 8, 20238-KResults of OperationsMay 8, 2023DEF 14ADEF 14AMay 1, 20238-KCompany UpdateMar 13, 202310-K10-KFeb 28, 20238-KResults of OperationsFeb 28, 202310-Q10-QNov 3, 20228-KResults of OperationsNov 2, 20228-KExecutive ChangeOct 28, 20228-KExecutive ChangeOct 13, 202210-Q10-QAug 9, 20228-KResults of OperationsAug 8, 20228-KExecutive Change · Shareholder VoteJun 10, 202210-Q10-QMay 5, 20228-KResults of OperationsMay 4, 2022DEF 14ADEF 14AApr 29, 20228-KExecutive ChangeApr 8, 202210-K10-KMar 1, 20228-KResults of OperationsFeb 28, 2022SC 13GSC 13GFeb 14, 2022SC 13GSC 13GFeb 4, 20228-KCompany UpdateDec 21, 20218-KExecutive ChangeDec 14, 20218-KCompany UpdateDec 6, 202110-Q10-QNov 9, 20218-KResults of OperationsNov 8, 20218-KExecutive ChangeNov 5, 20218-KExecutive ChangeSep 2, 202110-Q10-QAug 5, 20218-KResults of OperationsAug 4, 20218-KShareholder VoteJun 24, 202110-Q10-QMay 6, 20218-KResults of OperationsMay 5, 2021
Insider Activity
In the 90 days to Mar 26, 2026: 5 sold $770K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 26, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Sell | 3,171 | $21.65 | $69K |
| Mar 26, 2026 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER | Sell | 1,097 | $21.65 | $24K |
| Mar 26, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Sell | 37 | $21.72 | $804 |
| Mar 26, 2026 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER | Sell | 12 | $21.73 | $261 |
| Mar 25, 2026 | Owen Adams CatherineChief Executive Officer | Sell | 11,641 | $21.47 | $250K |
| Mar 25, 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Sell | 4,177 | $21.47 | $90K |
| Mar 25, 2026 | Rhodes Jennifer JEVP, CHIEF LEGAL OFFICER, SEC | Sell | 3,844 | $21.47 | $83K |
| Mar 25, 2026 | Thompson Elizabeth H.Z.EVP, Head of Research & Dev | Sell | 3,435 | $21.47 | $74K |
| Mar 25, 2026 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER | Sell | 833 | $21.47 | $18K |
| Feb 9, 2026 | Rhodes Jennifer JEVP, CHIEF LEGAL OFFICER, SEC | Sell | 6,950 | $23.38 | $162K |
| Nov 18, 2025 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Sell | 10,262 | $23.69 | $243K |
| Nov 18, 2025 | Kihara JamesPRINCIPAL ACCOUNTING OFFICER | Sell | 4,084 | $23.69 | $97K |
| Nov 10, 2025 | Daly James MDirector | Sell | 30,000 | $22.37 | $671K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance